Cargando…
Peptide-MHC-Based Nanomedicines for the Treatment of Autoimmunity: Engineering, Mechanisms, and Diseases
The development of autoimmunity results from a breakdown of immunoregulation and involves cellularly complex immune responses against broad repertoires of epitope specificities. As a result, selective targeting of specific effector autoreactive T- or B-cells is not a realistic therapeutic option for...
Autores principales: | Serra, Pau, Santamaria, Pere |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870702/ https://www.ncbi.nlm.nih.gov/pubmed/33574822 http://dx.doi.org/10.3389/fimmu.2020.621774 |
Ejemplares similares
-
Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines
por: Umeshappa, Channakeshava Sokke, et al.
Publicado: (2019) -
MHC Class II Polymorphisms, Autoreactive T-Cells, and Autoimmunity
por: Tsai, Sue, et al.
Publicado: (2013) -
Recognition of Multiple Hybrid Insulin Peptides by a Single Highly Diabetogenic T-Cell Receptor
por: Parras, Daniel, et al.
Publicado: (2021) -
Structural plasticity in I-A(g7) links autoreactivity to hybrid insulin peptides in type I diabetes
por: Erausquin, Elena, et al.
Publicado: (2022) -
Optimized Peptide–MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells
por: Dolton, Garry, et al.
Publicado: (2018)